Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Gotham Asset Management LLC

Gotham Asset Management LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,949 shares of the medical research company's stock after acquiring an additional 3,805 shares during the period. Gotham Asset Management LLC owned approximately 0.08% of Bio-Rad Laboratories worth $7,210,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Ethic Inc. increased its holdings in shares of Bio-Rad Laboratories by 48.5% during the 4th quarter. Ethic Inc. now owns 1,598 shares of the medical research company's stock worth $525,000 after buying an additional 522 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Bio-Rad Laboratories by 46.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 24,625 shares of the medical research company's stock worth $8,090,000 after buying an additional 7,837 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Bio-Rad Laboratories by 2.8% during the 4th quarter. Deutsche Bank AG now owns 37,601 shares of the medical research company's stock worth $12,352,000 after buying an additional 1,027 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Bio-Rad Laboratories by 648.0% during the 4th quarter. Captrust Financial Advisors now owns 5,730 shares of the medical research company's stock worth $1,882,000 after buying an additional 4,964 shares during the last quarter. Finally, Caxton Associates LP acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $590,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Royal Bank of Canada dropped their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. UBS Group dropped their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $327.40.

Bio-Rad Laboratories Trading Up 2.2%

Bio-Rad Laboratories stock traded up $5.26 during trading on Friday, hitting $248.45. The company had a trading volume of 254,950 shares, compared to its average volume of 321,515. Bio-Rad Laboratories, Inc. has a 1-year low of $215.38 and a 1-year high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company's 50 day simple moving average is $243.46 and its 200-day simple moving average is $298.10. The stock has a market cap of $6.96 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.30 earnings per share. As a group, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.